NCT06695130, the second vaccine candidate, combines SNY’s influenza recombinant protein-based trivalent vaccine, Flublok with NVXC19. SNY markets Fluzone High-Dose and Flublok flu vaccines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback